External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies

Prostate-specific membrane antigen targeted therapy with 177Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer. To optimise the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities. Therefore, this study aimed at estimating the ambient radiation exposure received by the patient.